Swiss Chemicals Stock News

If you are wondering whether Julius Bär Gruppe is fairly priced or offering value right now, the key is to look past the share price and focus on what different valuation methods are actually saying. The stock most recently closed at CHF 65.60, with returns of a 0.5% decline over 7 days, 2.1% over 30 days, a 0.3% decline year to date, 14.3% over 1 year, 21.5% over 3 years and 47.2% over 5 years. This gives you a mix of shorter term softness and longer term gains to weigh. Recent coverage of...

Avolta (SWX:AVOL) has secured the duty free concession at Shanghai Pudong Terminal 1, a rare win for an international travel retailer in mainland China that reshapes investor attention on its China exposure. See our latest analysis for Avolta. The Shanghai Pudong win comes at a time when Avolta’s CHF51.95 share price has a 30 day share price return of 10.63% and a 90 day share price return of 17.75%. Its 1 year total shareholder return of 30.73% contrasts with a 5 year total shareholder...

EFG International (SWX:EFGN) has attracted fresh attention after reporting full year 2025 results, with net income and earnings per share broadly steady while net interest income declined over the same period. See our latest analysis for EFG International. The earnings release and upcoming March AGM have come after a softer 30 day share price return of 5.22% and a year to date share price return of a 4.83% decline. This is despite the 1 year total shareholder return of 40.71% and 5 year total...

Logitech International (SWX:LOGN) is back in focus after management highlighted firm demand for premium peripherals and enterprise video collaboration, growing China gaming sales, secured memory supply into fiscal 2027, and continued share repurchases and dividend increases. See our latest analysis for Logitech International. At a share price of CHF71.1, Logitech has seen a 2.3% 1 day and 2.3% 7 day share price gain, set against a 90 day share price decline of 21.3% and a 1 year total...

DKSH Holding (SWX:DKSH) has drawn fresh attention after reporting full year 2025 earnings, which showed slightly lower sales and net income, along with board changes and a confirmed CHF 2.50 per share annual dividend. See our latest analysis for DKSH Holding. Against this backdrop, DKSH Holding’s 30 day share price return of 9.28% and 90 day share price return of 11.23% contrast with a 1 year total shareholder return of 9.53% and 3 year total shareholder return of 12.13%. This suggests recent...

Sandoz Group (SWX:SDZ) has drawn fresh attention after reporting full year 2025 earnings, with sales of US$11,086 million and net income of US$914 million, alongside progress in its expanding biosimilars portfolio. See our latest analysis for Sandoz Group. Sandoz Group's 1 day share price return of 2.87% contrasts with a 7 day share price return of 4.64% and a 90 day share price return of 24.01%. The 1 year total shareholder return of 80.41% points to strong momentum around its biosimilars...

Julius Bär Gruppe (SWX:BAER) has appointed Winfried Daun as Global Head of Brand & Marketing in a newly created leadership role. The company has introduced new model portfolios for UK financial advisers as part of an expanded UK wealth management approach. Julius Bär Gruppe, a Swiss private banking group, focuses on wealth management services for high net worth and ultra high net worth clients. The new marketing appointment and the UK model portfolios arrive as many wealth managers look to...

Alcon FY 2025 earnings: revenue push with mixed profit signals Alcon (SWX:ALC) has wrapped up FY 2025 with fourth quarter revenue of US$2.7 billion and basic EPS of US$0.44, alongside trailing 12 month revenue of US$10.4 billion and basic EPS of US$1.99 that frame the latest print against a fuller year of performance. The company has seen quarterly revenue move from US$2.5 billion in Q4 2024 to US$2.7 billion in Q4 2025, while basic EPS shifted from US$0.57 to US$0.44 over the same period...

Nestlé (SWX:NESN) is in advanced talks to sell its ice cream business as part of a CEO led turnaround plan. The company has also begun a sale process for its waters and drinks division, pointing to a potential exit from sizeable parts of its portfolio. These moves follow pressure on profits linked to baby formula recalls and increasing demands from shareholders for change. Nestlé is one of the largest global consumer packaged food companies, with brands across coffee, pet care,...

Recently, ABB has seen elevated trading activity in pre-market sessions, supported by ongoing industrial demand and strong spending in robotics and electrification solutions. An interesting angle is that third-party AI-driven models are flagging medium-term growth opportunities for ABB, even as some valuation concerns remain. We’ll now examine how this renewed confidence in robotics and automation demand fits into, and potentially reshapes, ABB’s existing investment narrative. The future of...

If you are wondering whether Amrize is priced fairly or if there could be value on the table, this article will walk through what the current share price might be telling you. Amrize shares last closed at CHF 50.14, with returns of 13.7% over the past week, 16.7% over the past month and 12.7% year to date, which may have changed how investors view its potential and its risks. Recent attention around Amrize has prompted fresh interest in how the company is being valued, with investors looking...

Sika (SWX:SIKA) has agreed to acquire Turkey based adhesives and sealants manufacturer Akkim. The deal is part of Sika’s Strategy 2028 to expand its adhesives and sealants business globally. The planned transaction increases Sika’s production footprint and presence in high growth markets. Sika focuses on specialty chemicals for construction and industrial applications, and adhesives and sealants are a core part of that offering. By adding Akkim’s product range and manufacturing base in...

If you are wondering whether Partners Group Holding is currently offering fair value or a potential opportunity, looking closely at its valuation can help put the recent share price in context. The stock closed at CHF 852.60, with returns of 9.6% decline over 7 days, 20.2% decline over 30 days, 17.2% decline year to date, 33.2% decline over 1 year, 7% return over 3 years and 11.2% decline over 5 years. These moves may have changed how the market views its risk and potential. Recent coverage...

If you are wondering whether Nestlé shares still justify their price, you are not alone; the stock often attracts investors who care about what they are actually paying for each franc of underlying business. Nestlé shares last closed at CHF81.40, with returns of 1.5% over 7 days, 12.3% over 30 days, 6.5% year to date, and a 3.9% decline over 1 year, 17.8% decline over 3 years, and 3.3% decline over 5 years, hinting at changing views on its growth and risk profile. Recent headlines around...

If you are wondering whether Cosmo Pharmaceuticals at CHF116.20 is priced attractively or already baking in a lot of optimism, this article walks through what the numbers say about its value. The stock shows returns of 0.5% over 7 days, 1.8% over 30 days, 10.2% year to date, 76.5% over 1 year, 105.4% over 3 years and 53.4% over 5 years, which may prompt questions about how much of this performance is supported by fundamentals. Recent coverage has focused on Cosmo Pharmaceuticals' position...

Amrize (SWX:AMRZ) has drawn fresh attention after issuing upbeat 2026 revenue guidance, outlining both ordinary and special dividend proposals, and attracting supportive analyst commentary following its recent spin off. See our latest analysis for Amrize. After the guidance, dividend proposals and recent board and auditor changes, Amrize’s 7 day share price return of 9.34% and 90 day share price return of 20.79% suggest building positive momentum from a starting point of CHF49.15. If this has...

Event driven repositioning at Partners Group Holding Partners Group Holding (SWX:PGHN) is in focus after shifting capital away from technology and software toward AI linked infrastructure assets, while its open ended private credit funds avoided net redemptions during recent sector volatility. See our latest analysis for Partners Group Holding. The recent repositioning toward AI linked infrastructure comes after a mixed run for investors, with a 30 day share price return of 14.25% decline, a...

Cembra Money Bank AG has already reported its full-year 2025 results, with net interest income of CHF 372.16 million and net income of CHF 179.57 million, and announced an annual dividend of CHF 4.60 per share, ex-date April 28, 2026. While net interest income eased slightly from the prior year, higher net income and an increased dividend highlight the bank’s ability to convert its lending activities into growing shareholder distributions. Next, we’ll examine how the higher net income and...

Sika (SWX:SIKA) has wrapped up FY 2025 with Q4 revenue of CHF 2.6b and net income of CHF 174.1m, while Q4 basic EPS came in at CHF 1.09. Over the past few quarters, the company has reported revenue of CHF 2.8b and EPS of CHF 2.02 in Q4 2024, CHF 2.9b in Q3 2025, and CHF 2.6b in Q4 2025. This sets up a results season where investors are likely to focus on how these changes in revenue and EPS relate to margins. See our full analysis for Sika. With the latest figures on the table, the next step...

EFG International (SWX:EFGN) has reported its FY 2025 results with second half revenue of CHF 864.5 million and basic EPS of CHF 0.34, alongside net income excluding extra items of CHF 112.8 million. The group has seen revenue move from CHF 753.4 million and basic EPS of CHF 0.49 in the second half of 2024 to CHF 793.8 million and basic EPS of CHF 0.71 in the first half of 2025. Trailing twelve month revenue of CHF 1.66 billion and basic EPS of CHF 1.03 set the broader context for today’s...

Cosmo Pharmaceuticals (SWX:COPN) has drawn attention after a strong share price move in recent months, prompting investors to look more closely at how its gastroenterology, dermatology, and healthtech portfolio lines up with current expectations. See our latest analysis for Cosmo Pharmaceuticals. At a share price of CHF122.6, Cosmo Pharmaceuticals has logged a 9.66% 1 month share price return and an 81.90% 3 month share price return. The 1 year total shareholder return of 89.84% suggests...

As European markets experience volatility amid global concerns over AI disruptions, the pan-European STOXX Europe 600 Index has managed to hit new highs, reflecting resilience in the face of these challenges. In this environment, dividend stocks can offer a measure of stability and income potential for investors seeking to navigate uncertain times.

This article is designed to help you think clearly about whether Alcon's current share price fairly reflects its potential or if the market might be mispricing it. Alcon closed at $61.90, with a 1.4% gain over the last 7 days, a 3.2% decline over 30 days, a 2.6% decline year to date, and a 23.6% decline over the past year, which may catch the eye of investors reassessing the balance between opportunity and risk. Recent headlines around Alcon have focused on its position within healthcare and...

As European markets navigate volatility amid AI disruption concerns and digest strong U.S. job data, the pan-European STOXX Europe 600 Index managed to hit a new high, reflecting resilience in the region's economy. In such an environment, dividend stocks can offer investors a measure of stability and income potential, making them an attractive consideration for those looking to balance growth with steady returns.